Acelyrin Q3 2024 Earnings Report
Key Takeaways
ACELYRIN reported their Q3 2024 financial results, highlighting a cash position of $562.4 million, which is projected to fund operations until mid-2027. They also completed a positive end of Phase 2 interaction with the FDA for lonigutamab and anticipate initiating a subcutaneous Phase 3 development program in thyroid eye disease (TED) in Q1 2025. Topline data from the Phase 2b/3 trial of izokibep for uveitis is expected in December 2024.
Cash, cash equivalents, and short-term marketable securities totaled $562.4 million as of September 30, 2024, expected to fund operations to mid-2027.
Completed a positive end of Phase 2 interaction with the FDA for lonigutamab.
Initiation of subcutaneous Phase 3 development program in thyroid eye disease (TED) expected in Q1 2025.
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024.
Acelyrin
Acelyrin
Forward Guidance
ACELYRIN expects to report topline data from the trial in December 2024.